• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Confirmed: Valeant to Buy Dendreon

Article

Following reports last week of a bid, it has now been confirmed that the Canadian company Valeant Pharmaceuticals International Inc will buy Provenge-maker Dendreon.

Valeant Pharmaceuticals International Inc will scoop up bankrupt cancer vaccine maker Dendreon Corp, after no additional qualified bids came forward by Tuesday's deadline, Valeant said.

A potential buyer dropped from the bidding process, three sources close to the sale told Reuters earlier.

Valeant, of Laval, Quebec, will get Seattle-based Dendreon's Provenge cancer treatment and other assets for $400 million in cash.

Complete news on Reuters: http://reut.rs/17hWY2r

Related Videos
Joshua K. Sabari, MD
Nicoletta Colombo, MD, PhD
Dr Brian Mulherin
Dr Brian Koffman
Dr Brian Mulherin
Dr Vivek Subbiah
Dr Scott Soefje
Dr Scott Soefje
Dr Mark Fendrick
Related Content
The report offers strong evidence affirming previous reports suggesting that people with obesity may be at a heightened risk of DLBCL. | Image Credit: zhuan - stock.adobe.com

Genetic Obesity Linked With DLBCL Risk

October 28th 2025
Article

New reporting suggests obesity and diffuse large B-cell lymphoma (DLBCL) have shared genetic risk factors.

Read More

Managed Care Cast

Navigating Risk, Treatment, and Reimbursement in Precision Oncology: Sadie Dobrozsi, MD

July 15th 2025
Podcast

Sadie Dobrozsi, MD, of Evolent, discusses how predictive genomics is pushing cancer care into a new era of personalization

Listen

Combining CAR T cells with first-line therapies like immune checkpoint inhibitors may ultimately prove to be the best method of deployment for CAR T in SCLC. | Image credit: Alpha Tauri 3D - stock.adobe.com

CAR T-Cell Therapy Holds Potential in SCLC, but Significant Barriers Remain

October 8th 2025
Article

Early research has identified several antigens that could help facilitate the use of chimeric antigen receptor T cells in small cell lung cancer.

Read More

managed care cast logo

Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions

October 24th 2024
Podcast

On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.

Listen

The authors said blood-based biomarkers for ICI response should be a research priority in soft tissue sarcoma moving forward. | Image credit: Dzmitry - stock.adobe.com

Blood-Based Biomarkers Could Reshape Soft Tissue Sarcoma Therapy

September 30th 2025
Article

Biomarkers like neutrophil-to-lymphocyte ratio could help predict treatment response to immune checkpoint inhibitors in certain patients with soft tissue sarcoma.

Read More

It is not uncommon for patients with SCLC to have distant metastases in areas such as the brain, liver, bone, and adrenal glands,but there are only scant reports of patients with SCLC who also have other primary malignancies. | Image credit: didesign - stock.adobe.com

Review Outlines Rare, Complicated Cases of Co-Occurring SCLC and GI Cancers

September 30th 2025
Article

Second primary malignancies in patients with small cell lung cancer are often misdiagnosed as distant metastases.

Read More

© 2025 MJH Life Sciences
AJMC®
All rights reserved.